DOCSLIB.ORG

Alcohol – the Body & Health Effects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alcohol – the Body & Health Effects Alcohol – the Body & Health Effects A brief overview 23 3 Contents 5 Introduction 21 Mental health conditions 5 What is alcohol? 22 Alcohol and drug interactions 6 Body effects of alcohol 23 Effects of alcohol on other people 9 Overall body effects 23 The unborn child 9 Blood and immune system 23 Children and families 9 Bones and muscles 24 Effects of alcohol on population groups 9 Brain and nervous system 24 Women 10 Breasts – women 24 Men 10 Eyes 25 Young people 10 Heart and blood pressure 25 Older people 11 Intestines 26 Low-risk alcohol drinking advice 11 Kidneys and fluid balance 26 How much? 11 Liver 27 Advice for parents of children and young people under 18 years 12 Lungs 27 What is a standard drink? 12 Mental health 28 When not to drink 12 Mouth and throat 28 Tips for low-risk drinking 13 Pancreas and digestion of sugar 28 Background to drinking advice Acknowledgements 13 Sexual health – men 29 Where to find support and further information 13 Sexual health – women The Alcohol Advisory Council of New Zealand (ALAC) would like to thank Dr Fiona Imlach Gunasekara, Public 30 Glossary Health Medicine Specialist, for preparing the summaries of the health and body effects of alcohol in this resource. 14 Skin and fat 32 References ISBN 978–1–927138–41–0 (print) 14 Stomach and food pipe (oesophagus) 978–1–927138–42–7 (online) 15 Health effects of acute alcohol use TABLES 15 Alcohol poisoning 7 Table 1: Symptoms of drunkenness at different 17 Hangover levels of blood alcohol concentration (BAC) Alcohol Advisory Council of New Zealand 18 Health conditions related to chronic alcohol use 16 Table 2: Potential symptoms and complications Kaunihera Whakatupato Waipiro o Aotearoa of acute intoxication or alcohol poisoning, by 20 Cancers body part affected PO Box 5023 20 Cardiovascular disease Wellington 19 Table 3: Potential conditions and complications New Zealand 6145 21 Existing health conditions – impact of alcohol of chronic and/or heavy episodic alcohol use, by body part affected alac.org.nz | waipiro.org.nz | June 2012 21 Diabetes mellitus 5 Introduction Introduction Introduction Support & Information Effects Health & Conditions Impact of Alcohol Drinking Advice Body This resource provides a brief What is alcohol? overview of the health and body Alcohol (ethanol or ethyl alcohol) is the ingredient effects of alcohol. It is a series found in beer, wine and spirits which causes of short summaries based on drunkenness. Alcohol is formed when yeast ferments available evidence rather than (breaks down without oxygen) the sugars in different foods; for example wine is made from the sugar in a comprehensive literature grapes, beer from the sugar in malted barley (a type of review. Areas covered include grain), cider from the sugar in apples, and vodka from the effects of alcohol on body the sugar in potatoes, beets or other plants.[1] parts, the health effects of acute alcohol use, the health conditions related to chronic alcohol use, and the effects of alcohol on other people and populations. Low-risk drinking advice is also outlined in this resource along with information about where to find support and further information. 6 7 Introduction Body effects of alcohol Effects Body Health Effects & Conditions Impact of Alcohol Effects of Alcohol Drinking Advice Support & Information Health Effects & Conditions Impact of Alcohol Drinking Advice Alcohol is classed as a ‘sedative The BAC rises, and the feeling of drunkenness occurs, when alcohol is drunk faster than the liver can break hypnotic’ drug,[2] which means Table 1: Symptoms of drunkenness at different levels of blood alcohol concentration (BAC) it acts to depress the central it down. Table 1 shows the relationship between BAC and symptoms of drunkenness – the higher the BAC, nervous system at high doses. the greater the effects on the body. However, BAC does BAC Symptoms not correlate exactly with symptoms of drunkenness <50 mg/dL Some impairment in motor coordination and thinking ability At lower doses, alcohol can act as a stimulant,[3] and different people have different symptoms even Talkativeness inducing feelings of euphoria and talkativeness, after drinking the same amount of alcohol. The BAC Relaxation but drinking too much alcohol at one session can level, and every individual’s reaction to alcohol, is lead to drowsiness, respiratory depression (where influenced by: [1,2,7] breathing becomes slow, shallow or stops entirely), 50-150 mg/dL Altered mood (increased well-being or unhappiness) coma or even death.[4–6] • the ability of the liver to metabolise alcohol (which Friendliness, shyness or argumentativeness varies due to genetic differences in the liver enzymes Impaired concentration and judgement As well as its acute and potentially lethal sedative that break down alcohol)[7] Sexual disinhibition effect at high doses, alcohol has effects on every • the presence or absence of food in the stomach organ in the body, and these effects depend on 150-250 mg/dL Slurred speech (food dilutes the alcohol and dramatically slows the blood alcohol concentration (BAC) over time.[7] Unsteady walking its absorption into the bloodstream by preventing Nausea After a drink is swallowed, the alcohol is rapidly it from passing quickly into the small intestine) Double vision absorbed into the blood (20 percent through the • the concentration of alcohol in the beverage Increased heart rate stomach and 80 percent through the small intestine), (highly concentrated beverages such as spirits Drowsiness with effects felt within 5 to 10 minutes after drinking.[6] are more quickly absorbed) Mood, personality and behaviour changes which may be It usually peaks in the blood after 30 to 90 minutes,[6] sudden, angry and antisocial and thus is carried through all the organs of the body. • how quickly alcohol is drunk • body type (heavier and more muscular people have 300 mg/dL Unresponsive/extremely drowsy Most (90 percent) of the metabolism, or breaking more fat and muscle to absorb the alcohol)[2] Speech incoherent/confused down, of alcohol from a toxic substance to water Memory loss • age, sex, ethnicity (e.g. women have a higher BAC and carbon dioxide is performed by the liver,[6] Vomiting after drinking the same amount of alcohol than men with the rest excreted through the lungs (allowing Heavy breathing alcohol breath tests), through the kidneys (into urine) due to differences in metabolism and absorption – and in sweat.[8] since men have on average more fluid in their body >400 mg/dL Breathing slowed, shallow or stopped to distribute alcohol around than women do; some Coma The liver can break down only a certain amount ethnic groups have different levels of a liver enzyme Death of alcohol per hour, which for an average person responsible for the breakdown of alcohol) is around one standard drink (which raises the • how frequently a person drinks alcohol (someone BAC about 15 to 20 mg/dL[8] – the current limit who drinks often can tolerate the sedating effects for driving in New Zealand is 80 mg/dL). of alcohol more than someone who does not regularly drink).[6] Adapted from: Table 163.1 in Brust, J. C. M. (2005). Alcoholism. In L. P. Rowland (Ed.), Merritt’s neurology (11th ed.). Philadelphia: Lippincott Williams & Wilkins.[4] and Table 1 in Vonghia, L., Leggio, L., Ferrulli, A., Bertini, M., Gasbarrini, G., Addolorato, G., et al. (2008). Acute alcohol intoxication. European Journal of Internal Medicine, 19(8), 561–567.[5] 9 Overall body effects cells that fight infections), making it more difficult for Introduction Body effects of alcohol the body to fight off both viral and bacterial infections. > Alcohol affects all parts of the body including: People who drink heavily over a long time are more likely to suffer from infections after surgery, burns, Summary of main effects • blood and immune system trauma, hepatitis C infection, HIV/AIDS, meningitis, • bones and muscles blood Effects Body Alcohol affects all parts tuberculosis and pneumonia (acute inflammation Alcohol is absorbed into the • brain and nervous system of the body including: bloodstream and can have of the lung, usually due to infection).[4,14,15] some long-term effects. • breasts (in women) • eyes brain and Support & Information Health Effects & Conditions Impact of Alcohol Drinking Advice mental health nervous system • heart and blood pressure Bones and muscles Alcohol can be used to Alcohol impairs judgement • intestines relax but it is also addictive and concentration. Long-term ImmedIate effects of aLcohoL use and can lead to dependency. alcohol use can damage the • kidneys and fluid balance Alcohol use causes many different types of injuries, brain and nerves. • liver eyes including injuries from road traffic accidents, assaults Being drunk can • lungs and falls.[9] This is usually because high levels of blood cause blurred vision. lungs Being drunk and chronic • mental health alcohol impair the brain’s thought processes and skin heavy alcohol use can • mouth and throat the coordination of muscles, causing clumsiness and Alcohol use can have direct and increase the risk of difficulty walking.[16] Common injuries seen at the infections of the lungs. • pancreas and digestion of sugar indirect effects on the skin. emergency department include cuts, bruises, sprains • sexual and reproductive system – men and broken bones.[17,18] The risk of injury in the six mouth and throat heart • sexual and reproductive system – women hours after drinking doubles with four standard drinks Being drunk can cause Alcohol use at low levels may slurred speech. be beneficial for the heart in • skin and fat and increases rapidly the more alcohol is drunk on some people but is harmful for • stomach and food pipe (oesophagus). a single occasion.[19] breasts everyone at high levels. (in women) As well as potentially affecting the physical and mental Long-term effects of aLcohoL use Long-term alcohol liver health of individuals in many ways, chronic and heavy Moderate alcohol use may protect against osteoporosis use increases the Long-term alcohol use alcohol use can increase the risk of death[9] either (thinning of the bones, which makes the bones more risk of breast cancer.
Load more

Recommended publications
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Gamma Hydroxybutyrate (GHB)
    If you have issues viewing or accessing this file, please contact us at NCJRS.gov. PROPERTY OF Executive Office of the President National CriminalJustice Reference Service (NOJRS) ~.~1~<~ ~ )~ Office of National Drug Control Policy Box 6000 \~~/ Rockvilte, MD 20849-6000 L lohn P. Waiters, Director www.whitchousedrugpolicy.gov 1-800-666-333~ Gamma Hydroxybutyrate (GHB) / Backgrou nd liquid packaged in vials or sma.ll bottles. In liquid form, Gamma hydroxybutyrate (GHB) is a powerful, rapidly it is clear, odorless, tasteless, and almost undetectable acting central nervous system depressant. It was first when mixed in a drink. GHB is typically consumed by synthesized in the 1920s and was under development as the capful or teaspoonful at a cost of $5 to $10 per dose. an anesthetic agent in the 1960s. GHB is produced nat- The average dose is I to 5 grams and takes effect in 15 urally by the body in small amounts but its physiologi- to 30 minutes, depending on the dosage and purity of cal function is unclear. the drug. Its effects last from 3 to 6 hours. GHB was sold in health food stores as a performance- Consumption of less than l gram of GHB acts as a enhancing additive in bodybuilding formulas until the relaxant, causing a loss of muscle tone and reduced Food and Drug Administration (FDA) banned it in inhibitions. Consumption of I to 2 grams causes a 1990. It is currently marketed in some European coun- strong feeling of relaxation and slows the heart rate tries as an adjunct to anesthesia. GHB is abused for its and respiration.
    [Show full text]
  • Sedative / Hypnotics
    Sedative / Hypnotics Robert Althoff, MD, PhD www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose: ▪ I receive or have received research support from NIMH, NIDA, and the Klingenstein Third Generation Foundation ▪I have ownership equity in WISER Systems, LLC as a partner. www.mghcme.org www.mghcme.org • Sedative / Hypnotics are a general class of agents • Frequently refer to benzodiazepines (and like compounds) and barbiturates • Many similarities in mechanisms of action, medical indications, behavioral effects, withdrawal considerations, and treatment www.mghcme.org Benzodiazepine Mechanism of Action Benzodiazepines are a class of agents that work on the central nervous system, acting selectively on gamma-aminobutyric acid-A (GABA-A) receptors in the brain. It enhances response to the inhibitory neurotransmitter GABA, by opening GABA-activated chloride channels and allowing chloride ions to enter the neuron, making the neuron negatively charged and resistant to excitation www.mghcme.org • Traditional benzodiazepines – Diazepam (Valium) – Clonazepam (Klonopin) – Others • “Z” Drugs – Zaleplon (trade: Sonata) – Zolpidem (trade: Ambien, Edluar, Intermezzo) – Zopiclone (trade: Zimovane) www.mghcme.org Benzodiazepine: General Info • C IV DEA classification • Although more than 2,000 different benzodiazepines have been produced worldwide, only about 15 are currently FDA-approved in the United States. • Types of benzodiazepines therefore include those the following – Ultra-short acting: midazolam (Versed), triazolam (Halcion) – Short-acting: alprazolam (Xanax), lorazepam (Ativan) – Long-acting: chlordiazepoxide (Librium), diazepam (Valium) • The use of benzodiazepines during pregnancy is a risk factor for cleft lip or palate, lower muscle tone, and withdrawal symptoms in the developing fetus Bachhuber, et al.
    [Show full text]
  • Doxepin (Silenor) for Insomnia DHIREN PATEL, Pharmd, and JENNIFER D
    STEPS New Drug Reviews Doxepin (Silenor) for Insomnia DHIREN PATEL, PharmD, and JENNIFER D. GOLDMAN-LEVINE, PharmD Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts STEPS new drug reviews Silenor is a new low-dose formulation of the tricyclic antidepressant doxepin (which is typi- cover Safety, Tolerability, cally taken as a 25- to 150-mg dose at bedtime). Low-dose doxepin is labeled for the treatment Effectiveness, Price, and Simplicity. Each indepen- of insomnia characterized by difficulty maintaining sleep. The exact mechanism by which the dent review is provided medication exerts its sleep maintenance effect is unknown, but is thought to be antagonism 1 by authors who have no of histamine H1 receptors. financial association with the drug manufacturer. The series coordinator for Drug Dosage Dose form Monthly cost* AFP is Allen F. Shaugh- nessy, PharmD, Tufts Doxepin (Silenor) 3 to 6 mg daily 3-mg and 6-mg tablets $208 University Family Medicine Residency Program at *—Price for 30 3-mg or 6-mg tablets at CVS Pharmacy on May 18, 2011. Cambridge Health Alli- ance, Malden, Mass. A collection of STEPS pub- lished in AFP is available SAFETY of 1,017 patients, approximately 1 percent at http://www.aafp.org/ 1 afp/steps. Doxepin is safe when used at low dosages. withdrew because of adverse effects. Rebound Antidepressants are required to have label- insomnia and withdrawal symptoms have not ing that warns of an increased risk of sui- been reported. Next-day sedation, anticholin- cide; however, there have been no reports ergic effects, and memory impairment do not of suicide among patients taking low-dose occur at low dosages.2,3 The use of central ner- doxepin.
    [Show full text]
  • Phenibut and EMS Earlier This Week, the Michigan Poison Center
    Phenibut and EMS Earlier this week, the Michigan Poison Center (MPP) received an inquiry from a UP emergency physician who had cared for two patients in two days who had been abusing a substance called Phenibut, a synthetically produced central nervous system depressant with similarities to the neurotransmitter known as GABA. Phenibut is not an FDA approved or regulated drug. It typically is marketed as a dietary substitute and is readily available in stores (especially “headshops”) and online. While officially considered a supplement, it is felt to have properties more similar to a prescription sedative. It is marketed outside of the US for depression, anxiety, and posttraumatic stress disorder. Recently Phenibut has been recognized as having the potential for physical dependence, withdrawal, and addiction.1,2 In response to the UP physician’s concern that these two cases might be part of an increase in Phenibut use, the MPC initiated a review, identifying 12 cases this year.3 They also notified MDHHS of the concern. The Division of EMS and Trauma, using Michigan EMS Information System data identified 8 cases in the first 11 months of 2019 compared to 5 cases in the last 6 months of 2018. One EMS case was also identified by MPC. Of the combined 19 cases from 2019, one third occurred in the Upper Peninsula, with 5 of the 8 cases (62.5%) in the last 6 months coming from the UP. Cases were reported in 10 Michigan counties. Documented coingestants were noted in 36.8% of the cases and included cannabinoids (2), kratom (3), ETOH, Flakka (bath salts), and other medications.
    [Show full text]
  • Therapeutic Class Overview Sedative Hypnotics
    Therapeutic Class Overview Sedative Hypnotics Therapeutic Class • Overview/Summary: Insomnia is the most common sleep disorder in adulthood, affecting 33 to 69% of the population. It is estimated that five to ten percent of adults experience specific insomnia disorders.1,2 Insomnia is a disorder that results from a difficulty in initiating or maintaining sleep, waking too early, or sleep that is considered nonrestorative or poor quality.1-3 Furthermore, individuals with insomnia must also report at least one of the following types of daytime impairment as a result of the difficulties experienced with sleep: fatigue/malaise; impairment in memory, attention, or concentration; social or work-related dysfunction; poor school performance; irritability; day time sleepiness; loss of motivation, energy, or initiative; increased tendency for work or driving related accidents/errors; tension headaches; gastrointestinal symptoms; or concerns/worries about sleep. In individuals with insomnia, these complaints occur despite having sufficient opportunity and circumstances for sleep.1,2 According to the International Classification of Sleep Disorders, insomnia may be classified as one of the following: short-term insomnia, chronic insomnia or other insomnia (defined as patients who experience difficulty initiating or maintaining sleep but do not meet all of the criteria for either short-term or chronic insomnia).2 There are several classes of medications available for the management of insomnia.4-6 Doxepin (Silenor®) is a tricyclic antidepressant that
    [Show full text]
  • Sedatives Every Day Q
    ? Q&A IF I HAVE BEEN TAKING SEDATIVES EVERY DAY Q. FOR A FEW WEEKS OR LONGER, IS IT SAFE TO STOP TAKING SEDATIVES WHENEVER I WANT? A. NO. Talk to your doctor. Withdrawal symptoms can be life-threatening and include seizures, increased heart rate, blood pressure, and temperature, as well as visual hallucinations.5 AREN’T SEDATIVES LESS DANGEROUS THAN Q. OTHER DRUGS? SEDATIVES NO. In fact, sedative overdoses have increased. A. A recent study showed that the most commonly prescribed sedatives called benzodiazepines THE TRUTH ABOUT SEDATIVES were responsible for nearly 30 percent of deaths from medications.6 SLANG: BENZOS/PHENNIES/ ARE SEDATIVES LESS HARMFUL THAN RED BIRDS/REDS/YELLOW Q. DRINKING? JACKETS/ YELLOWS/DOWNERS/ NO. The effects of sedatives can be harmful and 1 A. are similar to alcohol intoxication. Symptoms SLEEPING PILLS/TRANKS include impaired attention and judgment, inappropriate behavior, decreased reflexes, and lack of balance when walking.7 GET THE FACTS THE BOTTOM LINE: Even when used as directed, sedatives carry risk. But SEDATIVES CAN BE ADDICTIVE. Although sedatives are often when misused, sedatives are more dangerous and can used to treat insomnia, they can be harmful when taken in ways even be deadly. Talk to your parents, a doctor, a counselor, other than as prescribed by a doctor, such as to self-medicate for a teacher, or another adult you trust if you have questions. depression or anxiety. Long-term use may result in needing larger doses to achieve the desired sedation and calming effects, which LEARN MORE: can lead to addiction.2 In some cases it is possible to misjudge how Get the latest information on how drugs affect the brain much more is needed, leading to overdose.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • Gamma-Hydroxybutyric Acid (GHB) Critical Review Report
    Gamma-hydroxybutyric acid (GHB) Critical Review Report Expert Committee on Drug Dependence Thirty-fifth Meeting Hammamet, Tunisia, 4-8 June 2012 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) 2 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) Acknowledgements This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Medicines Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this critical review report: Dr. Louis S. Harris, USA (literature review and drafting), Dr Caroline Bodenschatz (editing) and Mr Kamber Celebi, France (questionnaire report). 3 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) 4 35th ECDD (2012) Agenda item 4.1 Gamma-hydroxybutyric acid (GHB) Contents SUMMARY ............................................................................................................................... 7 1. Substance Identification ....................................................................................................... 9 A. International Non-proprietary Name (INN) .............................................................. 9 B. Chemical Abstract Service (CAS) Registry Number ................................................. 9 C. Other chemical names ............................................................................................... 9 D. Trade names .............................................................................................................
    [Show full text]
  • Patterns of European Diagnoses and Prescribing
    Patterns of European Diagnoses and Prescribing Bernie O'Brien Health Economics Research Department of Economics, Brunei University ®hE Office of Health Economics 12 Whitehall London SW1A2DY January 1984 Patterns of European Diagnoses and Prescribing Bernie O'Brien Health Economics Research Department of Economics, Brunei University ®hE Office of Health Economics 12 Whitehall London SW1A2DY January 1984 Office of Health Economics The Office of Health Economics was founded in 1962 by the Association of the British Pharmaceutical Industry. Its terms of reference are: To undertake research on the economic aspects of medical care. To investigate other health and social problems. To collect data from other countries. To publish results, data and conclusions relevant to the above. The Office of Health Economics welcomes financial support and discussions on research problems with any persons or bodies interested in its work. 2 Contents List of tables (see Appendix B) Introduction 5 Table 1 Population characteristics 1982 Table 2 Mortality and health indicators 1 Diagnosis analysis Table 3 Smoking and alcohol consumption 1.1 The context: Europe's changing health 6 Table 4 Diagnoses and prescriptions: summary 1.2 Some predisposing factors 6 table Table 5 Italy: leading diagnoses 1.3 Consultations and diagnoses 7 Table 6 Spain: leading diagnoses 1.4 Range and specificity of diagnoses 7 g Table 7 UK: leading diagnoses 1.5 Top twenty diagnoses by ICD chapter g Table 8 Germany: leading diagnoses 1.6 Top twenty diagnoses by ICD number Table 9 France:
    [Show full text]
  • Sedative Hypnotic Panel (Date Rape Panel), Urine
    Lab Dept: Chemistry Test Name: SEDATIVE HYPNOTIC PANEL, URINE General Information Lab Order Codes: SHP Synonyms: Date Rape Panel, Urine CPT Codes: 80307 – Drug test(s), presumptive, any number of drug classes Test Includes: Ethyl Alcohol, Barbiturates, Flunitrazepam, Benzodiazepines, Ketamine, and Gamma-Hydroxybutyric Acid Logistics Test Indications: N/A Lab Testing Sections: Chemistry - Sendouts Referred to: MedTox Laboratories (MedTox Test: 19253) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours Turnaround Time: 7 days Special Instructions: N/A Specimen Specimen Type: Aliquot of random or spot urine collection Container: Screw-capped urine container without preservative Draw Volume: 10 mL urine Processed Volume: Same as Draw Volume Collection: Random or spot urine collection Special Processing: Lab Staff: Aliquot urine into a screw-capped plastic vial without preservative. Store and ship at refrigerated temperatures. Ambient or frozen temperature is acceptable. Forward promptly. Patient Preparation: None Sample Rejection: Mislabeled specimens or unlabeled specimens Interpretive Reference Range: Drug Screened: Reference Range: Positives Confirmed, reported as follows: Alcohol, Ethyl Negative gm/dL Barbiturates Negative ng/mL Flunitrazepam Negative ng/mL Benzodiazepine Negative ng/mL Ketamine Negative ng/mL Gamma- Negative ug/mL Hydroxybutyric Acid Critical Values: Alcohol, Ethyl – High 0.300 gm/dL Limitations: Alcohol, Ethyl – reporting limit: 0.020 gm/dL Gamma-Hydroxybutyric Acid reporting limit: 5.0 ug/mL Methodology: Ethyl Alcohol: Screen – Enzymatic method, Confirmation - Gas chromatography All other drugs: Screen – Immunoassay, Confirmation – GC/MS References: MedTox Laboratories January 2015 Update: 5/6/210: CPT updates 2/8/2011: CPT updates 1/5/2015: CPT updates 5/18/2015: CPT update 1/20/2016: CPT update 2/2/2016: CPT update 11/6/2017: CPT update .
    [Show full text]
  • Sedative-Hypnotics: Pharmacology and Use
    CLINICAL REVIEW Sedative-Hypnotics: Pharmacology and Use Norman S. Miller, MD, and Mark S. Gold, MD White Plains, New York, Summit, New Jersey, and Delray Beach, Florida The quest for an ideal sedative-hypnotic drug has been fraught with failure. The goals of the perfect sedative-hypnotic drug are to: (1) produce a transient reduc­ tion in the level of consciousness for the purpose of sedation, calmness, and tran­ quility without lingering aftereffects: (2) produce sleep without the potential to ar­ rest respirations and without aftereffects on sensorium and mood; and (3) produce no abuse, addiction, tolerance, or dependence. Nonetheless, clinical conditions have required the use of sedative-hypnotic drugs in spite of the inher­ ent difficulties with them. The history of sedative-hypnotic drugs is replete with attempts to produce a safe and effective drug. The introduction of one sedative-hypnotic drug for an­ other has been heralded by unguarded optimism and misguided claims. History has repeated itself with each new drug. Toxicities, abuse, addiction, and develop­ ment of tolerance and dependence have remained in force for each drug that has appeared on the market. Only minor variations on a theme have differentiated one drug from another as the essential features have remained in force. he members of the class of sedative-hypnotic drugs are were initially considered to have less potential for abuse, Tremarkably similar in their pharmacological proper­ they may be equal to the sedative-hypnotic drugs in these ties but vary considerably in their chemical structure. The respects.3-4 method of classification arose primarily as an attempt to Other members of the sedative-hypnotic class are chlo­ categorize the drugs according to the subjective and be­ ral hydrate, ethchlorvynol, glutethimide, meprobamate, havioral effects produced by them, that is, sedation and methyprylon, paraldehyde, and triclofos.
    [Show full text]